CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Celldex Therapeutics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Celldex Therapeutics, Inc.
53 Frontage Rd Ste 220
Phone: (908) 200-7500p:908 200-7500 HAMPTON, NJ  08827-4034  United States Ticker: CLDXCLDX

Business Summary
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board LarryEllberger 70 9/3/2009 8/12/2003
President, Chief Executive Officer, Director Anthony S.Marucci 57 12/4/2008 3/7/2008
Chief Financial Officer, Senior Vice President, Secretary SamMartin 48 7/1/2017 1/1/2015
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
CuraGen Corporation 322 East Main Street Branford CT United States
Kolltan Pharmaceuticals Inc 300 George St Ste 530 NEW HAVEN CT United States

Business Names
Business Name
Celldex Australia PTY LTD
Celldex Therapeutics Switzerland GmbH
CLDX
Kolltan Pharmaceuticals Inc

General Information
Number of Employees: 137 (As of 12/31/2018)
Outstanding Shares: 15,904,520 (As of 9/30/2019)
Shareholders: 209
Stock Exchange: NASD
Federal Tax Id: 133191702
Fax Number: (908) 454-1911
Email Address: info@avantimmune.com


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 15, 2019